Biomarkers as potential treatment targets in inflammatory bowel disease: A systematic review

Canadian Journal of Gastroenterology and Hepatology

Volumn 29, Issue 4, 2015, Pages 203-208

  Murdoch, Travis B ^a   O'Donnell, Sarah ^b   Silverberg, Mark S ^b   Panaccione, Remo ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Anti tumour necrosis factor therapy; Biomarker; C reactive protein; Crohn disease; Fecal calprotectin; Ulcerative colitis

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALGRANULIN; HEMOGLOBIN; LACTOFERRIN; TUMOR NECROSIS FACTOR INHIBITOR;

ANEMIA; COLON RADIOGRAPHY; COLON RESECTION; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; DISEASE MARKER; ENDOSCOPY; ERYTHROCYTE SEDIMENTATION RATE; HEMOGLOBIN BLOOD LEVEL; HOSPITAL PATIENT; HUMAN; HYPOALBUMINEMIA; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; LEUKOCYTE ADHERENCE; MAINTENANCE THERAPY; MONOTHERAPY; PRIORITY JOURNAL; RELAPSE; REMISSION; REVIEW; SYSTEMATIC REVIEW; TH17 CELL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS; CHEMISTRY; FECES; INFLAMMATORY BOWEL DISEASES; METABOLISM; PATHOLOGY;

BIOMARKERS; C-REACTIVE PROTEIN; FECES; HUMANS; INFLAMMATORY BOWEL DISEASES;

EID: 84928941030     PISSN: 22912789     EISSN: 22912797     Source Type: Journal    
DOI: 10.1155/2015/389548     Document Type: Review

References (64)

1. Solomon DH, Bitton A, Katz JN, Radner H, Brown EM, Fraenkel L. Review: Treat to target in rheumatoid arthritis: Fact, fiction, or hypothesis? Arthritis Rheumatol 2014;66:775-82.
2. Pepys MB, Hirschfield GM. C-reactive protein: A critical update. J Clin Invest 2003;111:1805-12.
3. Szalai AJ, McCrory MA, Cooper GS, Wu J, Kimberly RP. Association between baseline levels of C-reactive protein (CRP) and a dinucleotide repeat polymorphism in the intron of the CRP gene. Genes Immun 2002;3:14-9.
4. Carlson CS, Aldred SF, Lee PK, et al. Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels. Am J Hum Genet 2005;77:64-77.
5. Colombel JF, Solem CA, Sandborn WJ, et al. Quantitative measurement and visual assessment of ileal Crohn's disease activity by computed tomography enterography: Correlation with endoscopic severity and C reactive protein. Gut 2006;55:1561-7.
6. Jones J, Loftus EV, Panaccione R, Chen LS. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's Disease. Clin Gastroenterol Hepatol 2008;6:1218-24.
7. Solem CA, Loftus EV, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005;11:707-12.
8. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357:228-38.
9. Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebocontrolled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005;129:807-18.
10. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
11. Stack WA, Mann SD, Roy AJ, et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet 1997;349:521-4.
12. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117:761-9.
13. Lamireau T, Cézard J-P, Dabadie A, et al. Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease. Inflamm Bowel Dis 2004;10:745-50.
14. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: The CLASSIC-I trial. Gastroenterology 2006;130:323-3.
15. van Assche G, Magdelaine-Beuzelin C, D'Haens G, et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: A randomized trial. Gastroenterology 2008;1341861-8.
16. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95.
17. Reinisch W, Wang Y, Oddens BJ, Link R. C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: A post-hoc analysis from ACCENT I. Aliment Pharmacol Ther 2012;35:568-76.
18. Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008;135:1130-41.
19. Toedter GP, Blank M, Lang Y, Chen D. Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn's disease. Am J Gastroenterol 2009;104:2768-73.
20. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med 2003;348:24-32.
21. MacDonald JK, McDonald JW. Natalizumab for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2007;(1):CD006097.
22. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699-710.
23. Treton X, Bouhnik Y, Mary J-Y, et al. Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: A high risk of relapse. Clin Gastroenterol Hepatol 2009;7:80-5.
24. Lémann M, Mary J-Y, Colombel J-F, et al. A randomized, doubleblind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology 2005;128:1812-8.
25. Louis E, Mary J-Y, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012;142:63-70.e5.
26. Sands BE, Tremaine WJ, Sandborn WJ, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: A pilot study. Inflamm Bowel Dis 2001;7:83-8.
27. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76.
28. Panes J, Esteve M, Cabre E, et al. Comparison of heparin and steroids in the treatment of moderate and severe ulcerative colitis. Gastroenterology 2000;119:903-8.
29. Romano C, Famiani A, Comito D, Rossi P, Raffa V, Fries W. Oral beclomethasone dipropionate in pediatric active ulcerative colitis: A comparison trial with mesalazine. J Pediatr Gastroenterol Nutr 2010;50:385-9.
30. Gordon FH, Hamilton MI, Donoghue S, et al. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther 2002;16:699-705.
31. Kumar S, Ghoshal UC, Aggarwal R, Saraswat VA, Choudhuri G. Severe ulcerative colitis: Prospective study of parameters determining outcome. J Gastroenterol Hepatol 2004;19:1247-52.
32. Henriksen M, Jahnsen J, Lygren I, et al. C-reactive protein: A predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut 2008;57:1518-23.
33. Turner D, Mack D, Leleiko N, et al. Severe pediatric ulcerative colitis: A prospective multicenter study of outcomes and predictors of response. Gastroenterology 2010;138:2282-91.
34. Aceituno M, Garcia-Planella E, Heredia C, et al. Steroid-refractory ulcerative colitis: Predictive factors of response to cyclosporine and validation in an independent cohort. Inflamm Bowel Dis 2008;14:347-52.
35. Cacheux W, Seksik P, Lémann M, et al. Predictive factors of response to cyclosporine in steroid-refractory ulcerative colitis. Am J Gastroenterol 2008;103:637-42.
36. Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut 1996;38:905-10.
37. Ricanek P, Brackmann S, Perminow G, et al. Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers. Scand J Gastroenterol 2011;46:1081-91.
38. Røseth AG, Fagerhol MK, Aadland E, Schjønsby H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992;27:793-8.
39. Abraham BP, Kane S. Fecal markers: Calprotectin and lactoferrin. Gastroenterol Clin North Am 2012;41:483-95.
40. Vestergaard TA, Nielsen SL, Dahlerup JF, Hornung N. Fecal calprotectin: Assessment of a rapid test. Scand J Clin Lab Invest 2008;68:343-7.
41. Burri E, Beglinger C. Faecal calprotectin-a useful tool in the management of inflammatory bowel disease. Swiss Med Wkly 2012;142:w13557.
42. Konikoff MR, Denson LA. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis 2006;12:524-34.
43. Bunn SK, Bisset WM, Main MJ, Gray ES, Olson S, Golden BE. Fecal calprotectin: Validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001;33:14-22.
44. Røseth AG, Aadland E, Jahnsen J, Raknerud N. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997;58:176-80.
45. Limburg PJ, Ahlquist DA, Sandborn WJ. Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am J Gastroenterol 2000;95:2831-7.
46. D'Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012;18:2218-24.
47. Sipponen T, Savilahti E, Kärkkäinen P, et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNFalpha therapy for Crohn's disease. Inflamm Bowel Dis 2008;14:1392-8.
48. Wagner M, Peterson CGB, Ridefelt P, Sangfelt P, Carlson M. Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease. World J Gastroenterol 2008;14:5584-9.
49. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013;369:711-21.
50. Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: Unexpected results of a randomised, double-blind placebocontrolled trial. Gut 2012;61:1693-700.
51. Gisbert JP, Bermejo F, Perez-Calle J-L, et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis 2009;15:1190-8.
52. De Vos M, Louis EJ, Jahnsen J, et al. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. Inflamm Bowel Dis 2013;19:2111-7.
53. Molander P, af Björkesten C-G, Mustonen H, et al. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents. Inflamm Bowel Dis 2012;18:2011-7.
54. Yamamoto T, Shiraki M, Bamba T, Umegae S, Matsumoto K. Fecal calprotectin and lactoferrin as predictors of relapse in patients with quiescent ulcerative colitis during maintenance therapy. Int J Colorectal Dis 2014;29:485-91.
55. Parikh A, Leach T, Wyant T, et al. Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis 2012;18:1470-9.
56. Gisbert JP, McNicholl AG, Gomollon F. Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. Inflamm Bowel Dis 2009;15:1746-54.
57. Silberer H, Küppers B, Mickisch O, et al. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome. Clin lab 2005; 51:117-26.
58. Schröder O, Naumann M, Shastri Y Prospective evaluation of faecal neutrophil-derived proteins in identifying intestinal inflammation: Combination of parameters does not improve diagnostic accuracy of calprotectin. Aliment Pharmacol Ther 2007;26:1035-42.
59. Turner D, Leach ST, Mack D, et al. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: A prospective multicentre comparison of predicting outcomes and monitoring response. Gut 2010;59:1207-12.
60. Kabakchiev B, Turner D, Hyams J, et al. Gene expression changes associated with resistance to intravenous corticosteroid therapy in children with severe ulcerative colitis. PLoS ONE 2010;5:e13085.
61. Lee JC, Espéli M, Anderson CA, et al. Human SNP links differential outcomes in inflammatory and infectious disease to a FOXO3-regulated pathway. Cell 2013;155:57-69.
62. Pham MX, Teuteberg JJ, Kfoury AG, et al. Gene-expression profiling for rejection surveillance after cardiac transplantation. N Engl J Med 2010;362:1890-900.
63. van Roon JAG, Tesselaar K, Radstake TRDJ. Proteome-wide analysis and CXCL4 in systemic sclerosis. N Engl J Med 2014;370:1563-4.
64. D'Inca R, Dal Pont E, Di Leo V, et al. Can calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastroenterol 2008;103:2007-14.